The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
Open accessAbstract
Schizophrenia is the eighth leading cause of disability worldwide in people aged 15–44 years. Before antidopaminergic antipsychotics were introduced in the 1950s, no effective medications existed for the treatment of schizophrenia. This review summarizes key meta-analytic findings regarding antipsychotic efficacy in the acute treatment of schizophrenia, including clozapine in treatment-resistant patients. In the most comprehensive meta-analysis of randomized controlled trials conducted in multi-episode schizophrenia, antipsychotics outperformed placebo regarding total symptoms, positive symptoms, negative symptoms, depressive symptoms, quality of life and social functioning. Amongst these outcomes, the standardized mean difference for overall symptoms was largest, that is, 0.47 (95% credible interval = 0.42–0.51), approaching a medium effect size, being reduced to 0.38 when publication bias and small-trial effects were accounted for. A comparison of two meta-analyses indicated that first-episode patients, compared with multi-episode patients, were more likely to have at least minimal treatment response [⩾20% Positive and Negative Syndrome Scale (PANSS)/Brief Psychiatric Rating Scale (BPRS) score reduction: 81% versus 51%] and good response (⩾50% PANSS/BPRS score reduction: 52% versus 23%). In multi-episode schizophrenia, no response or worsening after 2 weeks of a therapeutic antipsychotic dose was highly predictive of not achieving a good response at endpoint (median treatment = 6 weeks: specificity = 86%; positive predictive value = 90%), suggesting a change in treatment should be considered in such cases. In first-episode psychosis, adequately dosed antipsychotic treatment trials for more than 2 weeks are recommended before using no response or worsening as a decision point for aborting a given antipsychotic. In clearly defined treatment-resistant schizophrenia, clozapine generally outperformed other antipsychotics, especially when dosed appropriately (target = 3–6 months’ duration; trough clozapine level ⩾350–400 μg/L) with a response rate (⩾20% PANSS/BPRS) of 33% by 3 months of treatment. High antipsychotic doses and psychotropic combinations are unlikely to be superior to standard doses of antipsychotic monotherapy. Acute antipsychotic efficacy in schizophrenia depends on the targeted symptom domain (greater efficacy: total and positive symptoms, lesser efficacy: negative symptoms, depressive symptoms, social functioning and quality of life). Greater antipsychotic efficacy is associated with higher total baseline symptom severity, treatment-naïveté/first-episode status, shorter illness duration, and trials that are nonindustry sponsored and that have a lower placebo effect. The heterogeneity of antipsychotic response across individuals and key symptom domains, the considerable degree of nonresponse/treatment resistance in multi-episode patients, and the adverse effect potential of antipsychotics are major limitations, underscoring the need to develop new medications for the treatment of schizophrenia. Drug development should include matching patient subgroups, which are identified by means of clinical and biomarker variables, to mechanisms of action of novel medications, targeting specific symptom domains, and investigating mechanisms of action other than dopaminergic blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Antipsychotic medication is the first line of treatment for SSD, showing effectiveness in managing positive symptoms like hallucinations and delusions but showing limited efficacy in addressing negative symptoms and cognitive impairment.10–12”
From Yoga-Based Group Intervention for Inpatients with Schizophrenia Spectrum Disorders—Feasibility, Acceptability, and Preliminary Outcomes of a Rater-Blinded Randomized Controlled Trial. (2026) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,350
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595
Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population
Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K. I., Isometsä, E. T., Pirkola, S. P., Partonen, T., Tuulio‐Henriksson, A., Hintikka, J., Kieseppä, T., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.1.19 · Cited by 1,523
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,328
Perkins, D., Gu, H., Boteva, K., & Lieberman, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1785 · Cited by 1,304
Howes, O. D., McCutcheon, R. A., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,187
Self-citationKahn, R. S., Sommer, I. E., Murray, R. M., Meyer‐Lindenberg, A., Weinberger, D. R., Cannon, T. D., O’Donovan, M. C., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,163
Self-citationLeucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670
Siskind, D. J., McCartney, L., Goldschlager, R., & Kisely, S. R. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 646
Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies
Haddad, P. M., Brain, C., & Scott, J. L. (2014) · Patient Related Outcome Measures · doi:10.2147/prom.s42735 · Cited by 617
Self-citationBarnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Self-citationLeucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., Samara, M., Rabaioli, M., Bächer, S., Cipriani, A., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16121358 · Cited by 542
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520
Self-citationJauhar, S., McKenna, P. J., Radua, J., Fung, E., Salvador, R., & Laws, K. R. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.116285 · Cited by 517
Leucht, S., Komossa, K., Rummel‐Kluge, C., Corves, C., Hunger, H., Schmid, F., Lobos, C. A., Schwarz, S., & Davis, J. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 499
Intensive case management for severe mental illness
Dieterich, M., Irving, C. B., Park, B., & Marshall, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007906.pub2 · Cited by 493
The Economic Burden of Schizophrenia in the United States in 2013
Cloutier, M., Aigbogun, M. S., Guérin, A., Nitulescu, R., Ramanakumar, A. V., Kamat, S., DeLucia, M., Duffy, R. A., Legacy, S. N., Henderson, C., et al. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10278 · Cited by 479
Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1228 · Cited by 408
Siskind, D. J., Siskind, V., & Kisely, S. R. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717718167 · Cited by 394
Lieberman, J. A., Safferman, A. Z., Pollack, S. Z., Szymanski, S., Johns, C. A., Howard, A., Kronig, M. H., Bookstein, P., & Kane, J. M. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1744 · Cited by 382
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 369
Howes, O. D., Vergunst, F., Gee, S., McGuire, P. K., Kapur, S., & Taylor, D. M. (2012) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.105833 · Cited by 355
History of the Discovery and Clinical Introduction of Chlorpromazine
Lopez-Munoz, F. J., Álamo, C., Cuenca, E., Shen, W. W., Clervoy, P., & Rubio, G. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230591002002 · Cited by 355
Dose Response and Dose Equivalence of Antipsychotics
Davis, J. M., & Chen, N. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117422.05703.ae · Cited by 354
Causes and consequences of duration of untreated psychosis in schizophrenia
Drake, R., Haley, C. J., Akhtar, S., & Lewis, S. W. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.6.511 · Cited by 347
Gallego, J. A., Bonetti, J., Zhang, J., Kane, J. M., & Correll, C. U. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.018 · Cited by 346
Self-citationPhenothiazine Treatment in Acute Schizophrenia
(1964) · Archives of General Psychiatry · doi:10.1001/archpsyc.1964.01720210028005 · Cited by 336
Linking the PANSS, BPRS, and CGI: Clinical Implications
Leucht, S., Kane, J. M., Etschel, E., Kissling, W., Hamann, J., & Engel, R. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301147 · Cited by 333
Treatment of the Neuroleptic-Nonresponsive Schizophrenic Patient
Meltzer, H. Y. (1992) · Schizophrenia Bulletin · doi:10.1093/schbul/18.3.515 · Cited by 332
Long-Term Follow-Up of the TIPS Early Detection in Psychosis Study: Effects on 10-Year Outcome
Hegelstad, W. T. V., Larsen, T. K., Auestad, B., Evensen, J. H., Haahr, U., Joa, I., Johannesen, J. O., Langeveld, J., Melle, I. S., Opjordsmoen, S., et al. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11030459 · Cited by 317
Guttmacher, M. S. (1964) · PubMed · Cited by 310
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia
Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2955 · Cited by 305
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Yang, A. C., & Tsai, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081689 · Cited by 286
Intensive case management for severe mental illness
Dieterich, M., Irving, C. B., Bergman, H., Khokhar, M. A., Park, B., & Marshall, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007906.pub3 · Cited by 271
What is an Adequate Trial with Clozapine?
Schulte, P. F. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00001 · Cited by 264
Clinical predictors of therapeutic response to antipsychotics in schizophrenia
Carbon, M., & Correll, C. U. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/mcarbon · Cited by 257
Self-citationLehmann, H. E. (1954) · A M A Archives of Neurology & Psychiatry · doi:10.1001/archneurpsyc.1954.02320380093011 · Cited by 251
Termination of Clozapine Treatment Due to Medical Reasons
Nielsen, J., Correll, C. U., Manu, P., & Kane, J. M. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08064 · Cited by 232
Self-citationCorrell, C. U., Rubio, J. M., Inczedy-Farkas, G., Birnbaum, M. L., Kane, J. M., & Leucht, S. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0624 · Cited by 214
Self-citationAntipsychotic treatment and mortality in schizophrenia.
Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Bjorkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu164 · Cited by 208
Samara, M. T., Leucht, C., Leeflang, M., Anghelescu, I., Chung, Y., Crespo‐Facorro, B., Elkis, H., Hatta, K., Giegling, I., Kane, J. M., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101329 · Cited by 201
Self-citationKinon, B. J., Chen, L., Ascher‐Svanum, H., Stauffer, V. L., Kollack‐Walker, S., Zhou, W., Kapur, S., & Kane, J. M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.164 · Cited by 183
Idänpään-Heikkilä, J. J., Alhava, E., Olkinuora, M., & PALVA, I. P. (1975) · The Lancet · doi:10.1016/s0140-6736(75)90206-8 · Cited by 181
Time Course for Antipsychotic Treatment Response in First-Episode Schizophrenia
Emsley, R. A., Rabinowitz, J., & Medori, R. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.4.743 · Cited by 162
Sommer, I. E., Begemann, M., Temmerman, A., & Leucht, S. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr004 · Cited by 159
Psychoeducation (brief) for people with serious mental illness
Zhao, S., Sampson, S. J., Xia, J., & Jayaram, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010823.pub2 · Cited by 157
Zhu, Y., Li, C., Huhn, M., Rothe, P., Krause, M., Bighelli, I., Schneider‐Thoma, J., & Leucht, S. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.06.011 · Cited by 147
Casey, J. F. (1960) · A M A Archives of General Psychiatry · doi:10.1001/archpsyc.1960.03590080086012 · Cited by 140
Vermeulen, J., van Rooijen, G., Doedens, P., Numminen, E., van Tricht, M., & de Haan, L. (2017) · Psychological Medicine · doi:10.1017/s0033291717000873 · Cited by 134
Zhu, Y., Krause, M., Huhn, M., Rothe, P., Schneider‐Thoma, J., Chaimani, A., Li, C., Davis, J. M., & Leucht, S. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30270-5 · Cited by 128
Ten-Year Outcomes of First-Episode Psychoses in the MRC ÆSOP-10 Study
Revier, C. J., Reininghaus, U., Dutta, R., Fearon, P., Murray, R. M., Doody, G. A., Croudace, T. J., Dazzan, P., Heslin, M., Onyejiaka, A. N., et al. (2015) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000295 · Cited by 118
Initial Severity of Schizophrenia and Efficacy of Antipsychotics
Furukawa, T. A., Levine, S. Z., Tanaka, S., Goldberg, Y., Samara, M. T., Davis, J. M., Cipriani, A., & Leucht, S. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2127 · Cited by 116
Time to clozapine response in a standardized trial
Conley, R. R., Carpenter, W. T., & Tamminga, C. A. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1243 · Cited by 106
The Role of Clozapine in Treatment-Resistant Schizophrenia
Kane, J. M., & Correll, C. U. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2966 · Cited by 98
Self-citationChlorpromazine in Psychiatry: A Study of Therapeutic Innovation
Swazey, J. P. (1974) · DigitalGeorgetown (Georgetown University Library) · Cited by 96
Determinants of Antipsychotic Response in Schizophrenia
Rabinowitz, J., Werbeloff, N., Caers, I., Mandel, F. S., Stauffer, V. L., Ménard, F., Kinon, B. J., & Kapur, S. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08853 · Cited by 81
Time to Treatment Response in First-Episode Schizophrenia
Gallego, J. A., Robinson, D. G., Sevy, S. M., Napolitano, B. A., McCormack, J., LESSER, M. L., & Kane, J. M. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06349 · Cited by 79
Carmona, V. R., Gómez‐Benito, J., Huedo-Medina, T. B., & Rojo, E. (2017) · International Journal of Occupational Medicine and Environmental Health · doi:10.13075/ijomeh.1896.01074 · Cited by 67
Leucht, S., Rossum, I. W.-V., Heres, S., Arango, C., Fleischhacker, W. W., Glenthoj, B. Y., Leboyer, M., Leweke, F. M., Lewis, S. W., McGuire, P. K., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv019 · Cited by 60
Emerging drugs for schizophrenia: an update
Köster, L.-S., Carbon, M., & Correll, C. U. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.958148 · Cited by 55
Self-citationCorrell, C. U., Kishimoto, T., & Kane, J. M. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/ccorrell · Cited by 49
Self-citationA STUDY OF PHENOTHIAZINES WITH MALE AND FEMALE CHRONICALLY ILL SCHIZOPHRENIC PATIENTS
Adelson, D., & Epstein, L. J. (1962) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196206000-00008 · Cited by 48
Management of clozapine-resistant schizophrenia
Kerwin, R., & Bolonna, A. A. (2005) · Advances in Psychiatric Treatment · doi:10.1192/apt.11.2.101 · Cited by 46
Leucht, S., Engel, R. R., Davis, J. M., Kissling, W., Capellen, K. M. Z., Schmauß, M., & Messer, T. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.11.007 · Cited by 40
Stentebjerg-Olesen, M., Jeppesen, P., Pagsberg, A. K., Fink‐Jensen, A., Kapoor, S., Chekuri, R., Carbon, M., Al‐Jadiri, A., Kishimoto, T., Kane, J. M., et al. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0007 · Cited by 32
Self-citationGaray, R. P., Citrome, L., Samalin, L., Liu, C., Thomsen, M. S., Correll, C. U., Hameg, A., & Llorca, P. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1149164 · Cited by 30
Self-citationWhat Are We Looking for in New Antipsychotics?
Correll, C. U. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10075su1.02 · Cited by 30
Self-citationAntipsychotic medication and long-term mortality risk in patients with schizophrenia
Vermeulen, J. M., van Rooijen, G., Doedens, P., Numminen, E., van Tricht, M. J., & de Haan, L. (2017) · Cited by 30
Schennach-Wolff, R., Obermeier, M., Seemüller, F., Jäger, M., Schmauß, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L., Gäebel, W., et al. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181faf39b · Cited by 27
Performance Improvement CME: Long-Term Treatment of Bipolar Disorder
McIntyre, R. S., & Wagner, K. D. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9089pi3cc · Cited by 9
Research works printed but not linked: 12
- World Health Organisation, 2001, The WHO World Health Report 2001 - Mental Health: New Understanding, New Hope
- A full list of the papers available in the Special Collection on Antipsychotics: Advances, Limitations, and Alternatives in Therapeutic Advances in Psychopharmacology is available at: http://journals.sagepub.com/page/tpp/special-collection/antipsychotics
- 10.1176/ajp.2006.163.4.743 · DOI
- Royal College of Psychiatrists, 2014, CR190 Consensus statement on High-dose Antipsychotic medication
- Ackenheil M, 1977, Psychotherapeutic drugs: part II, 923
- Idanpaan-Heikkila J, Lancet, 1975
- National Institute for Health and Care Excellence (NICE), 2014, Clinical guideline [CG178]
- 10.1176/ajp.151.12.1744 · DOI
- Albert C., 2017, Int J Mol Sci, 18
- Zhao S, 2015, Cochrane Database Syst Rev
- Dieterich M, 2017, Cochrane Database Syst Rev
- Carmona VR, 2017, Int J Occup Med Environ Health, 30, 345
Cited by
Sorted by citations
Jauhar, S., Johnstone, M., & McKenna, P. J. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01730-x · Cited by 1,116
Correll, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911
Self-citationBarnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Self-citationThe schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Tandon, R., Nasrallah, H. A., Akbarian, S., Carpenter, W. T., DeLisi, L. E., Gäebel, W., Green, M. F., Gur, R. E., Heckers, S., Kane, J. M., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.11.015 · Cited by 205
The Role of Inflammation in the Treatment of Schizophrenia
Fond, G. B., Lançon, C., Korchia, T., Auquier, P., & Boyer, L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00160 · Cited by 151
Metadata
- Authors
- Haddad, P. M., & Correll, C. U.
- Affiliations
- University of Manchester (GB)
- Hofstra University (US)
- Corresponding author
- Haddad, Peter M.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2018-10-08
- Volume
- 8
- Issue
- 11
- Pages
- 303-318
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC6180374
- OpenAlex
- W2897156727
- Cited by
- 259
- References
- 74
- Citations by year
- 2026: 31 · 2025: 36 · 2024: 45 · 2023: 46 · 2022: 31 · 2021: 33 · 2020: 23 · 2019: 12
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- schizophrenia, antipsychotic drugs, clozapine, treatment-resistant schizophrenia, first-episode psychosis, treatment response prediction, antipsychotic dosing, antipsychotic monotherapy, positive symptoms, negative symptoms, depressive symptoms, quality of life, social functioning, publication bias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
